trending Market Intelligence /marketintelligence/en/news-insights/trending/ZZm_ELEXWePXbpGLop52bA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Almirall inks option deal to acquire blood cancer drug maker Bioniz Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Almirall inks option deal to acquire blood cancer drug maker Bioniz Therapeutics

Almirall SA entered into an agreement that gives the company an option to acquire all of Bioniz Therapeutics Inc.'s outstanding shares for an initial payment of $15 million.

The acquisition will allow Barcelona-based Almirall to obtain the global rights to BNZ-1, Bioniz's drug candidate that blocks signaling molecules, called cytokines, of the same family, boosting the body's immune system to fight off malignant cancer cells. BNZ-1 is being developed to treat T cell blood cancers, including large granular lymphocyte leukemia and cutaneous T cell lymphoma — a group of rare and often aggressive leukemias with limited or no treatment options.

If Almirall exercises the option, the Spanish pharmaceutical company will also enter into a broader research deal to use Bioniz's multiple cytokine inhibitor platform to develop at least three new cancer therapies ready to be tested in humans.

Under the deal, Almirall will get 60 days to exercise its option after receiving results from Bioniz's phase 1/2 study in cutaneous T cell lymphoma, along with certain clinical biomarker data and a report from the company's meeting with the U.S. Food and Drug Administration.

With the option being exercised, Irvine, Calif.-based Bioniz will receive about $47 million in payments plus certain development, regulatory and commercial milestone fees.

Bioniz will spin off other assets than BNZ-1 as well as the proprietary platform technology, with Almirall pursuing the development of BNZ-1.

Bhushan Hardas, Almirall's chief scientific officer, said the acquisition expands the company's pipeline in oncodermatology and immunodermatology.